Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Clin Cancer Res. 2014 Apr 9;20(12):3146–3158. doi: 10.1158/1078-0432.CCR-13-2576

Figure 5. Effect of Imatinib and PLX3397 and/or Rapamycin on Iba-1.

Figure 5

A. Xenograft tissues obtained from mice at the end of 3-week treatment with the indicated drugs were stained immuno-histochemically using Iba-1 antibody. Scale bar (50μm) is shown in the right hand corner of each image. Images from a tumor obtained at the end of 3 week treatment from a representative experiment reproduced at lease three independent times are shown. B. Iba-1 signal (brown staining) was quantitated using MetaMorph image analysis software (Molecular Devices). Iba-1 signal was quantified from at least 3 different high power fields and plotted as arbitrary intensity units. (NS=Not Significant). Quantitation of Iba-1 signal from a tumor obtained from a representative experiment reproduced at lease three independent times is shown. C. Xenograft tissues obtained at the end of 1 week after stopping the drug treatment were stained immuno-histochemically using Iba-1 antibody. Scale bar (50μm) is shown in the right hand corner of each image. Images of a tumor obtained from a representative experiment reproduced at lease two independent times are shown. D. Iba-1 signal (brown staining) was quantitated using MetaMorph image analysis software (Molecular Devices). Iba-1 signal was quantified from at least 3 different high power fields and plotted as arbitrary intensity units. Quantitation of Iba-1 signal from a tumor obtained from a representative experiment reproduced at lease two independent times is shown.